PDCD1 and mature T-cell and NK-cell non-Hodgkin lymphoma: Pembrolizumab, an anti-PD-1 antibody, has been increasingly used in the literature surrounding malignancies such as melanoma and other non-Hodgkin lymphomas and has been explored in recurrent/relapsed (R/R) mature PTCL with an ORR of 33% (118).